ASP 4132

Drug Profile

ASP 4132

Alternative Names: ASP4132

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lymphoma; Solid tumours

Most Recent Events

  • 27 Apr 2018 Astellas Pharma completes a phase I trial in Lymphoma and Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO) (NCT02383368)
  • 01 Oct 2017 Discontinued - Phase-I for Lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (Astellas Pharma pipeline, November 2017)
  • 01 Oct 2017 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (Astellas Pharma pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top